

# Soluble Guanylate Cyclase - Pipeline Review, H1 2020

<https://marketpublishers.com/r/S618D58E7873EN.html>

Date: May 2020

Pages: 103

Price: US\$ 3,500.00 (Single User License)

ID: S618D58E7873EN

## Abstracts

Soluble Guanylate Cyclase - Pipeline Review, H1 2020

### SUMMARY

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity.

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 6, 4 and 14 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Cardiovascular, Ophthalmology, Metabolic Disorders, Respiratory, Gastrointestinal, Oncology, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders, Infectious Disease and Musculoskeletal Disorders which include indications Glaucoma, Ocular Hypertension, Pulmonary Arterial Hypertension, Diabetic Nephropathy, Diastolic Heart Failure, Lung Disease, Open-Angle Glaucoma, Vaso-Occlusive Crisis Associated With Sickle Cell Disease, Acute Heart Failure, Acute Respiratory Distress Syndrome, Alzheimer's Disease, Asthma, Chronic Kidney Disease (Chronic Renal Failure), Chronic Thromboembolic Pulmonary Hypertension, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Coronavirus Disease 2019 (COVID-19), Critical Limb Ischemia, Cystic Fibrosis, Diabetic Foot Ulcers, Diabetic Retinopathy, Dry (Atrophic) Macular

Degeneration, Ischemic Stroke, Liver Diseases, Liver Fibrosis, Mycobacterium Infections, Non-Alcoholic Steatohepatitis (NASH), Osteoporosis, Pancreatic Cancer, Pressure Ulcers, Prostate Cancer, Pulmonary Hypertension, Sickle Cell Disease, Skin Ulcers, Stroke, Systolic Heart Failure and Vascular Dementias.

The latest report Soluble Guanylate Cyclase – Pipeline Review, H1 2020, outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)

The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Soluble Guanylate Cyclase (sGC or

EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



## Contents

Introduction

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Overview

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Development

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Dormant Products

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Discontinued Products

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Indications, H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020  
Number of Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Products under Development by Companies, H1 2020 (Contd..2), H1 2020  
Number of Products under Investigation by Universities/Institutes, H1 2020  
Products under Investigation by Universities/Institutes, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Pipeline by AntiRadical Therapeutics LLC, H1 2020  
Pipeline by Bayer AG, H1 2020  
Pipeline by Boehringer Ingelheim International GmbH, H1 2020  
Pipeline by Cyclarion Therapeutics Inc, H1 2020  
Pipeline by Gurus BioPharm, H1 2020  
Pipeline by NicOx SA, H1 2020  
Pipeline by Novartis AG, H1 2020  
Pipeline by Novoteris LLC, H1 2020  
Pipeline by Toa Eiyo Ltd, H1 2020  
Pipeline by Topadur Pharma AG, H1 2020  
Dormant Products, H1 2020  
Dormant Products, H1 2020 (Contd..1), H1 2020  
Dormant Products, H1 2020 (Contd..2), H1 2020  
Dormant Products, H1 2020 (Contd..3), H1 2020  
Dormant Products, H1 2020 (Contd..4), H1 2020  
Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

AntiRadical Therapeutics LLC

Bayer AG

Boehringer Ingelheim International GmbH

Cyclerion Therapeutics Inc

Gurus BioPharm

NicOx SA

Novartis AG

Novoteris LLC

Toa Eiyo Ltd

Topadur Pharma AG

## I would like to order

Product name: Soluble Guanylate Cyclase - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/S618D58E7873EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S618D58E7873EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970